Table 3. Characteristics and outcomes of 15 patients who received treatment for relapse or progression after nonmyeloablative UCB transplantation.

Patient	Histological Diagnosis	Disease status at UCBT	Number of Prior Therapies	Time to relapse/ progression (days)	Time to acute GVHD (days)	Chimerism at the time of relapse/ progression	Treatment at relapse/progression	Time from relapse/ progression to treatment (months)	Response to treatment	Outcome
1	Diffuse Large cell B-Cell	Partial Remission	3	104	19	100%	taper immunosuppression* + rituximab†	< 1	CR	Alive
2	Diffuse Large cell B-Cell	Partial Remission	3§	6	51	82%	taper immunosuppression*,+ rituximab†	< 1	PROG	Dead
3	Diffuse Large cell B-Cell	Partial Remission	6	164	30	100%	rituximab†	5	CR	Alive
4	Diffuse Large cell B-Cell	Partial Remission	3	120	31	100%	taper immunosuppression* + rituximab†	5	CR	Alive
5	Diffuse Large cell B-Cell	Partial Remission	2§	21	No	100%	taper immunosuppression* + rituximab†	< 1	PROG	Dead
6	Diffuse Large cell B-Cell	Partial Remission	2	21	63	NA	rituximab† + radiotherapy¶	3	PROG	Dead
7	Diffuse Large cell B-Cell	Chemotherapy Refractory	3	211	No	100%	taper immunosuppression* + rituximab†	5	CR	Alive
8	Mantle cell lymphoma	Chemotherapy Refractory	2§	100	No	100%	taper immunosuppression* + chemotherapy + radio-immunotherapy	2	CR	Alive
9	Large cell T-Cell	Partial Remission	2	90	35	97%	radiotherapy	1	PROG	Dead
10	Anaplastic T Cell	Partial Remission	3	236	No	100%	taper immunosuppression*	< 1	CR	Alive
11	Follicular B-cell	Partial Remission	8	55	72	91%	rituximab†	6	CR	Alive
12	Follicular B-cell	Complete Remission	4	188	No	100%	taper immunosuppression* + rituximab†	3	CR	Alive
13	Follicular B-cell	Partial Remission	4	42	67	100%	taper immunosuppression*	1	PROG	Dead
14	Hodgkin Lymphoma	Complete Remission	4§	106	No	NA	taper immunosuppression* + chemotherapy + radiotherapy	18±	CR	Alive
15	Hodgkin Lymphoma	Partial Remission	9	88	15	100%	taper immunosuppression* + chemotherapy + radiotherapy	6	PROG	Dead

UCBT, umbilical cord blood transplantation; GVHD, graft-vs.-host- disease; CR, complete remission; PROG, progression

^*Taper of cyclosporine A and/or steroids started one to four weeks of diagnosis of relapse/progression.

^†Rituximab was dosed at 375 mg/m²/week for 4 weeks

^§Patient who underwent prior autologous transplant

^±Interval to last salvage therapy

^¶Palliative intent radiation therapy